Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1455467

registered interest
date	29/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the time taken to diagnose sarcoma cancer.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	149333
answer	answer is ministerial correction date of answer 04/04/2022 answer text <p>The ‘Delivery plan for tackling the COVID-19 backlog of elective care’ details how the National Health Service will reduce the time taken to diagnose cancer, including sarcoma cancer. The plan aims to return the number of people waiting more than 62 days from an urgent referral for cancer to pre-pandemic levels by March 2023. By March 2024, 75% of patients who have been urgently referred by their general practitioner (GP) for suspected cancer will be diagnosed or have cancer ruled out within 28 days.</p><p>The NHS is raising awareness of cancer symptoms through the ‘Help us help you’ campaign and locally tailored approaches to increase the number of referrals from GPs. We are investing £2.3 billion to establish up to 160 community diagnostic centres (CDCs) by March 2025. CDCs will provide additional capacity for tests which can assist the diagnosis of sarcoma cancer, such as ultrasounds, magnetic resonance imaging and biopsies. Since July 2021, existing CDCs have provided over 650,000 additional tests.</p><p>Those diagnosed with sarcoma and with a family history or risk factors can access genomic tests to aid early diagnosis and treatment options. There are also specialist soft tissue sarcoma cancer centres and specialist bone sarcoma centres in England. These centres accept referrals for patients with suspected diagnoses from genomics results or primary or acute care.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 149334 question first answered 04/04/2022 12:22:43 answering member 4492 label Biography information for Maria Caulfield
tabling member	4623 label Biography information for Tonia Antoniazzi

1437552

registered interest
date	02/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to prepare for the implementation of the UK NSC’s recommendation on lung cancer screening.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	133255
answer	answer is ministerial correction date of answer 07/03/2022 answer text <p>The UK National Screening Committee (UK NSC) plans to open a three-month public consultation on the evidence for lung cancer screening in the week commencing 7 March 2022. The Department will receive the UK NSC’s recommendation on lung cancer screening in individuals at an increased risk following its meeting in June 2022.</p><p>If recommended, NHS England and NHS Improvement will be responsible for implementing the programme in England and preparatory work is underway.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 07/03/2022 11:40:55 answering member 4492 label Biography information for Maria Caulfield
tabling member	4623 label Biography information for Tonia Antoniazzi

1437553

registered interest
date	02/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to COVID-19 Response: Living with COVID-19, published on 21 February 2022, what steps his Department are taking to help ensure that NHS England's Targeted Lung Health Check programme is able to return to and exceed its pre-pandemic levels of performance.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	133256
answer	answer is ministerial correction date of answer 07/03/2022 answer text <p>All Targeted Lung Health Check (TLHC) sites were operational by September 2020 and are issuing in excess of 30,000 invitations each month, compared to 1,555 each month prior to the pandemic. In 2022/23, the number of operational THLCs sites will increase from 23 to 43, funded by up to £70 million from the NHS Cancer Programme. The UK National Screening Committee is currently considering whether TLHCs should be recommended as a national screening programme.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 128399 128400 question first answered 07/03/2022 15:58:08 answering member 4492 label Biography information for Maria Caulfield
tabling member	4623 label Biography information for Tonia Antoniazzi

1437133

registered interest
date	01/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Epilepsy: Cannabis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, for what reason only three NHS prescriptions for medical cannabis have been issued to children with severe intractable epilepsy since the law was changed in November 2018 to enable those prescriptions to be made in specialist cases.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	132342
answer	answer is ministerial correction date of answer 08/03/2022 answer text <p>The licensed cannabis-based medicine Epidyolex is prescribed and routinely funded by the National Health Service for two rare forms of epilepsy - Dravet syndrome and Lennox-Gastaut syndrome.</p><p>Clinical guidelines from the National Institute for Health and Care Excellence demonstrate a need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based products for medicinal use. We continue to call on manufacturers to conduct this research and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 08/03/2022 09:07:39 answering member 4492 label Biography information for Maria Caulfield
tabling member	4623 label Biography information for Tonia Antoniazzi

1434765

registered interest
date	23/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his timeline is for approval of the national lung cancer screening programme following its suspension in March 2020 due to the covid-19 outbreak.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	128399
answer	answer is ministerial correction date of answer 07/03/2022 answer text <p>All Targeted Lung Health Check (TLHC) sites were operational by September 2020 and are issuing in excess of 30,000 invitations each month, compared to 1,555 each month prior to the pandemic. In 2022/23, the number of operational THLCs sites will increase from 23 to 43, funded by up to £70 million from the NHS Cancer Programme. The UK National Screening Committee is currently considering whether TLHCs should be recommended as a national screening programme.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 128400 133256 question first answered 07/03/2022 15:58:08 answering member 4492 label Biography information for Maria Caulfield previous answer version 53980 answering member constituency Lewes answering member printed Maria Caulfield answering member 4492 label Biography information for Maria Caulfield
tabling member	4623 label Biography information for Tonia Antoniazzi

1434766

registered interest
date	23/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, on what date will the lung screening pilots in England recommence following their suspension in March 2020.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	128400
answer	answer is ministerial correction date of answer 07/03/2022 answer text <p>All Targeted Lung Health Check (TLHC) sites were operational by September 2020 and are issuing in excess of 30,000 invitations each month, compared to 1,555 each month prior to the pandemic. In 2022/23, the number of operational THLCs sites will increase from 23 to 43, funded by up to £70 million from the NHS Cancer Programme. The UK National Screening Committee is currently considering whether TLHCs should be recommended as a national screening programme.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 128399 133256 question first answered 07/03/2022 15:58:08 answering member 4492 label Biography information for Maria Caulfield previous answer version 53981 answering member constituency Lewes answering member printed Maria Caulfield answering member 4492 label Biography information for Maria Caulfield
tabling member	4623 label Biography information for Tonia Antoniazzi

1434203

registered interest
date	22/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Education England: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what budget his Department has allocated to Health Education England for workforce growth and medical education in the financial year 2022-23.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	127510
answer	answer is ministerial correction date of answer 25/02/2022 answer text <p>Health Education England’s (HEE) budget for 2022/23 will be announced prior to 1 April 2022.</p><p>Spending plans for individual budgets, including for HEE’s budgets for workforce growth and medical education from 2022/23 to 2024/25, will be subject to a detailed financial planning exercise and finalised in due course.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 25/02/2022 14:53:38 answering member 4362 label Biography information for Edward Argar
tabling member	4623 label Biography information for Tonia Antoniazzi

1434207

registered interest
date	22/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Government's response to the Health and Social Care Select Committee’s report on Drugs Policy: Medicinal Cannabis, published in September 2019, what steps his Department has taken with the National Institute for Health Research to develop alternative research approaches to support children who are currently receiving cannabis-based products for medicinal use rather than randomised control trials, as set out in that response.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	127511
answer	answer is ministerial correction date of answer 25/02/2022 answer text <p>Research funding can be accessed through applications to the National Institute for Health Research (NIHR). The NIHR relies on researchers submitting high-quality applications and welcomes research proposals to evaluate the safety and clinical efficacy of cannabis-based products for medicinal use. The NIHR and the Medicines and Healthcare products Regulatory Agency (MHRA) will consider novel trial designs and it is not a specific requirement to conduct double blind trials. The MHRA has recently published guidance on the use of real-world data in clinical studies to support regulatory decisions.</p><p>The NIHR and the National Health Service will be supporting two randomised controlled trials into epilepsy. Alternative research approaches, such as an observational study, were considered in the trial design but discounted as it would not produce robust results nor add to the current evidence base.</p><p>In 2018, NHS England asked the British Paediatric Neurology Association (BPNA) to develop interim guidance for clinicians in the use and prescription of cannabis‐based products for medicinal use in children and young people with epilepsy. The National Institute for Health and Care Excellence (NICE) then published guidelines covering prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy. The BPNA has subsequently updated their guidance. As with all decisions to prescribe medicines, the General Medical Council expects doctors to use their professional judgement when deciding to what extent any clinical guidance is relevant.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 127512 127513 question first answered 25/02/2022 14:51:45 answering member 4492 label Biography information for Maria Caulfield
tabling member	4623 label Biography information for Tonia Antoniazzi

1434209

registered interest
date	22/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Government response to the Health and Social Care Select Committee’s report on Medicinal Cannabis in September 2019, what plans he has to ensure that the role of guidance from the BPNA relating to medical cannabis is replaced by the recently published guidance by NICE.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	127512
answer	answer is ministerial correction date of answer 25/02/2022 answer text <p>Research funding can be accessed through applications to the National Institute for Health Research (NIHR). The NIHR relies on researchers submitting high-quality applications and welcomes research proposals to evaluate the safety and clinical efficacy of cannabis-based products for medicinal use. The NIHR and the Medicines and Healthcare products Regulatory Agency (MHRA) will consider novel trial designs and it is not a specific requirement to conduct double blind trials. The MHRA has recently published guidance on the use of real-world data in clinical studies to support regulatory decisions.</p><p>The NIHR and the National Health Service will be supporting two randomised controlled trials into epilepsy. Alternative research approaches, such as an observational study, were considered in the trial design but discounted as it would not produce robust results nor add to the current evidence base.</p><p>In 2018, NHS England asked the British Paediatric Neurology Association (BPNA) to develop interim guidance for clinicians in the use and prescription of cannabis‐based products for medicinal use in children and young people with epilepsy. The National Institute for Health and Care Excellence (NICE) then published guidelines covering prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy. The BPNA has subsequently updated their guidance. As with all decisions to prescribe medicines, the General Medical Council expects doctors to use their professional judgement when deciding to what extent any clinical guidance is relevant.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 127511 127513 question first answered 25/02/2022 14:51:45 answering member 4492 label Biography information for Maria Caulfield
tabling member	4623 label Biography information for Tonia Antoniazzi

1434210

registered interest
date	22/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Epilepsy: Cannabis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the NHS Process Review of 8 August 2019 and the MHRA guidance issued in December 2021, if the Government will fund an alternative study into the potential merits of medical cannabis for children suffering from severe intractable epilepsy.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	127513
answer	answer is ministerial correction date of answer 25/02/2022 answer text <p>Research funding can be accessed through applications to the National Institute for Health Research (NIHR). The NIHR relies on researchers submitting high-quality applications and welcomes research proposals to evaluate the safety and clinical efficacy of cannabis-based products for medicinal use. The NIHR and the Medicines and Healthcare products Regulatory Agency (MHRA) will consider novel trial designs and it is not a specific requirement to conduct double blind trials. The MHRA has recently published guidance on the use of real-world data in clinical studies to support regulatory decisions.</p><p>The NIHR and the National Health Service will be supporting two randomised controlled trials into epilepsy. Alternative research approaches, such as an observational study, were considered in the trial design but discounted as it would not produce robust results nor add to the current evidence base.</p><p>In 2018, NHS England asked the British Paediatric Neurology Association (BPNA) to develop interim guidance for clinicians in the use and prescription of cannabis‐based products for medicinal use in children and young people with epilepsy. The National Institute for Health and Care Excellence (NICE) then published guidelines covering prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy. The BPNA has subsequently updated their guidance. As with all decisions to prescribe medicines, the General Medical Council expects doctors to use their professional judgement when deciding to what extent any clinical guidance is relevant.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 127511 127512 question first answered 25/02/2022 14:51:45 answering member 4492 label Biography information for Maria Caulfield
tabling member	4623 label Biography information for Tonia Antoniazzi